glp 1 fda ban Novo pressures GLP-1 compounders as takes hold 🚨 FDA UPDATE — April

It has been proposed that GLP 1 exerts a lipolytic effect by breaking down triglycerides into free fatty acids in pancreatic cells

The one letdown is tracking

106 However, once-weekly injectable GLP-1RA, semaglutide, increased medication adherence over other injectable administration schedules

However, is important to recognize that raising the BMI threshold could still present cost challenges given that the significant rebates that are usually available for this class of drugs may be significantly reduced or even unavailable at higher BMI thresholds

Severe abdominal pain, persistent vomiting, or signs of hypoglycaemia require prompt medical attention during the initial treatment period